- The traditional Chinese medicine industry is at a turning point in 2025, with nearly one-third of listed companies reporting revenue growth, but less than half achieving profit increases.
- The recent financial report from Pianzaihuang revealed a significant decline in revenue and net profit, confirming the industry's struggles as reliance on price increases and unique products wanes.
- As the market shifts, the industry must explore new growth strategies beyond price hikes, facing challenges such as rising raw material costs and changing consumer behavior.
